Has anyone tried to sell you peptides yet? If not, they probably will soon. Once a niche interest among bodybuilders and biohackers, peptides are now poised to enter the mainstream.

The Food and Drug Administration is set to discuss whether to reclassify a group of peptides so that pharmacies can legally make custom mixes. This move would reverse a decision made by the Biden administration in 2023, which barred certain peptides from being compounded. Although career scientists at the agency have recommended against it, many industry insiders believe the FDA will approve reclassification anyway.

The GLP-1 boom has warmed people up to the idea of injecting medications at home and proved to be a cash cow for pharmacies and virtual clinics. Now, companies like Hims & Hers Health are eager to expand their horizons by developing clinical protocols for peptides. Some of the largest telehealth companies have looked forward to this moment for over a year.

The peptide market is heating up with players like Mochi Health and Sapho Bio investing heavily in testing and validation. Even if this week’s meeting goes as expected, it won’t lead to an immediate green light for sellers. The next step involves a review period during which the FDA will propose rules and the public will be able to comment.